Published in Genes Dev on April 15, 1999
Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Neurofibromatosis type 2. Lancet (2009) 2.24
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res (2009) 1.25
Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol (2000) 1.16
Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants. Proc Natl Acad Sci U S A (2010) 0.98
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
Rac1 controls Schwann cell myelination through cAMP and NF2/merlin. J Neurosci (2012) 0.94
Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet (2000) 0.94
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol (2014) 0.91
The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet (2005) 0.90
A novel imaging-compatible sciatic nerve schwannoma model. J Neurosci Methods (2010) 0.88
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum Mol Genet (2014) 0.87
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res (2013) 0.84
p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. Glia (2014) 0.83
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol (2007) 0.82
Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (2002) 0.82
Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury. Neurobiol Dis (2015) 0.81
Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Ther (2009) 0.81
Cdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling. Glia (2013) 0.78
Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice. Otol Neurotol (2009) 0.78
In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. PLoS One (2014) 0.77
A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma. Nat Commun (2015) 0.76
Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nat Commun (2017) 0.75
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 6.29
Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface. EMBO J (1986) 5.60
Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res (1997) 3.70
Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res (1994) 3.00
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet (1996) 1.70
Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet (1994) 1.63
Spontaneous lesions in aging FVB/N mice. Toxicol Pathol (1997) 1.61
Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol (1998) 1.58
Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55
Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem (1998) 1.54
Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. Mod Pathol (1991) 1.53
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet (1996) 1.52
Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet (1998) 1.47
Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer (1995) 1.35
Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer (1996) 1.34
Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol (1981) 1.34
Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet (1998) 1.25
P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice. Neuron (1992) 1.23
Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res (1998) 1.21
Schwann cell differentiation. Curr Opin Cell Biol (1996) 1.20
The neurofibromatosis type 2 gene is inactivated in schwannomas. Hum Mol Genet (1994) 1.19
Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nat Genet (1998) 1.16
Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer (1995) 1.07
Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol (1997) 1.02
Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. Hum Mol Genet (1998) 1.00
Sympathetic innervation of the upper and lower regions of the uterus and cervix in the rat have different origins and routes. J Comp Neurol (1998) 0.99
Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet (1994) 0.95
Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain. Oncogene (1998) 0.95
Analysis of mutations in the SCH gene in schwannomas. Genes Chromosomes Cancer (1994) 0.93
Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. Cell Growth Differ (1998) 0.91
Analysis of molecular domains of epitope-tagged merlin isoforms in Cos-7 cells and primary rat Schwann cells. Exp Cell Res (1998) 0.89
Interphase cytogenetics for the detection of the t(11;22)(q24;q12) in small round cell tumors. J Clin Invest (1992) 0.89
Neurofibromatosis 2 gene has novel alternative splicings which controls intracellular protein binding. Int J Oncol (1997) 0.87
Cholinergic nerves in mouse uterus. J Neural Transm (1982) 0.82
Expression of nerve growth factor receptor in paraffin-embedded soft tissue tumors. Am J Pathol (1988) 0.82
Frequent expression of 75 kDa nerve growth factor receptor and phosphotyrosine in human peripheral nerve tumours: an immunohistochemical study on paraffin-embedded tissues. Virchows Arch (1994) 0.77
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg (2000) 13.24
Simplified mammalian DNA isolation procedure. Nucleic Acids Res (1991) 12.56
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet (2001) 9.55
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell (1991) 7.16
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Requirement for a functional Rb-1 gene in murine development. Nature (1992) 6.87
Drosophila S6 kinase: a regulator of cell size. Science (1999) 6.76
Phosphorylation and activation of p70s6k by PDK1. Science (1998) 6.53
Mammalian TOR: a homeostatic ATP sensor. Science (2001) 6.41
Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev (1994) 6.10
Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg (1998) 5.87
CARD15 mutations in Blau syndrome. Nat Genet (2001) 5.79
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev (2000) 5.71
Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J (1997) 5.57
Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell (1984) 5.56
Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell (1995) 5.54
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev (1999) 5.35
Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 5.34
Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature (1983) 5.14
Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J (1992) 5.05
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem (1992) 4.87
Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A (2001) 4.51
Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc Natl Acad Sci U S A (1992) 4.50
Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J (1994) 4.46
The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J (1995) 4.26
Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci U S A (1994) 4.16
Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev (2000) 4.05
Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res (1999) 4.04
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol (1996) 3.85
PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell (1998) 3.79
An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature (1995) 3.78
Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res (1997) 3.70
Activation of p70/p85 S6 kinase by a pathway independent of p21ras. Nature (1994) 3.67
A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep (2001) 3.67
Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature (2001) 3.65
Consecutive inactivation of both alleles of the pim-1 proto-oncogene by homologous recombination in embryonic stem cells. Nature (1990) 3.57
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature (2001) 3.57
Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell (1994) 3.57
Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules. J Exp Med (1997) 3.53
Structure of Moloney murine leukemia viral DNA: nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. Proc Natl Acad Sci U S A (1980) 3.53
Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol (1999) 3.50
In transgenic mice the introduced functional T cell receptor beta gene prevents expression of endogenous beta genes. Cell (1988) 3.34
Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) (2002) 3.33
Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell (1989) 3.31
Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J (1984) 3.28
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci U S A (1996) 3.09
Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science (2000) 3.07
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-beta-NGF in vivo. J Cell Biol (1990) 3.03
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant "Triton" tumors). Cancer (1973) 2.97
Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev (1997) 2.96
HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol (2000) 2.95
Transcription of T cell receptor beta-chain genes is controlled by a downstream regulatory element. EMBO J (1988) 2.93
p70s6k function is essential for G1 progression. Nature (1993) 2.91
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet (2000) 2.87
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg (1993) 2.87
The modular phosphorylation and activation of p70s6k. FEBS Lett (1997) 2.85
beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 2.82
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res (2001) 2.80
Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol (1996) 2.78
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proc Natl Acad Sci U S A (1999) 2.76
Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer (1990) 2.74
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med (1990) 2.73
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases. Am J Surg Pathol (1993) 2.71
The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol (1997) 2.66
M-MuLV-induced leukemogenesis: integration and structure of recombinant proviruses in tumors. Cell (1981) 2.65
Retroviral insertional mutagenesis: past, present and future. Oncogene (2005) 2.63
The effect of serum, EGF, PGF2 alpha and insulin on S6 phosphorylation and the initiation of protein and DNA synthesis. Cell (1982) 2.63
Characterization of AKR murine leukemia virus sequences in AKR mouse substrains and structure of integrated recombinant genomes in tumor tissues. J Virol (1981) 2.62
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
The enigma of desmoid tumors. Ann Surg (1999) 2.57
p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev (1998) 2.53
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev (1999) 2.48
Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet (1996) 2.47
Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J (1985) 2.47
Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J (1994) 2.44